Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

Abstract

This first comprehensive study of the molecular response to trastuzumab, pertuzumab and combined therapy in vivo highlights both common and distinct downstream effects to agents used alone or in combination, suggesting that complementary pathways may be involved.